Evidence map›Paper›PMID 36897556›Full record

ArticleInfectious diseases and therapy2023

Epidemiology of Clostridioides difficile Infections in Germany, 2010-2019: A Review from Four Public Databases.

Gordon Brestrich, Frederick J Angulo, Fabian K Berger, Christian Brösamle, Stefan Hagel, Andreas Leischker, Christoph Lübbert, Friederike Maechler, Sophie-Susann Merbecks, Nadia Minarovic and 6 more

Abstract read
In one paragraph

Article in Infectious diseases and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Clinical Characteristics and Risk Factors ofJournal of clinical medicine · 2026
    Article
  4. Clinical and molecular epidemiology ofFrontiers in microbiology · 2026
    Article
  5. Article
  6. Future microbiology · 2024
    Observational
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gordon BrestrichPfizer Pharma GmbH, Berlin, Germany. Gordon.brestrich@pfizer.com.ORCID http://orcid.org/0000-0002-1306-5474
Frederick J AnguloMedical Development and Scientific/Clinical Affairs, Pfizer Vaccines, Collegeville, USA.
Fabian K BergerInstitute of Medical Microbiology and Hygiene, University of Saarland, Homburg, Saar, Germany.
Christian BrösamleAMS Advanced Medical Services GmbH, Munich, Germany.
Stefan HagelInstitute for Infectious Diseases and Infection Control, University Hospital-Friedrich Schiller University, Jena, Germany.
Andreas LeischkerPhillips University, Marburg, Germany.
Christoph LübbertDepartment of Infectious Diseases/Tropical Medicine, Nephrology and Rheumatology, Hospital St. Georg, Leipzig, Germany.
Friederike MaechlerNational Reference Center for Surveillance of Nosocomial Infections, Berlin, Germany.
Sophie-Susann MerbecksHygiene and Environmental Medicine, Chemnitz, Germany.
Nadia MinarovicMedical Development and Scientific/Clinical Affairs, Pfizer Vaccines, Paris, France.
Jennifer C MoïsiMedical Development and Scientific/Clinical Affairs, Pfizer Vaccines, Paris, France.
Lutz von MüllerNational Reference Center for Clostridioides (Clostridium) Difficile, Homburg/Münster, Coesfeld, Germany.
Phillip A ReukenDepartment of Internal Medicine IV, University Hospital, Friedrich-Schiller-University, Jena, Germany.
Thomas WeinkeDepartment for Gastroenterology and Infection, Ernst Von Bergmann Clinic, Potsdam, Germany.
Holly YuHealth Economics and Outcomes Research, Pfizer Vaccines, Collegeville, USA.
Alexander MellmannNational Reference Center for Clostridioides (Clostridium) Difficile, Homburg/Münster, Coesfeld, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionClostridioides difficile infection (CDI) is a recognized global threat especially for vulnerable populations. It is of particular concern to healthcare providers as it is found in both hospital and community settings, with severe courses, frequent recurrence, high mortality and substantial financial impact on the healthcare system. The CDI burden in Germany has been described and compared by analysing data from four different public databases.

methodsData on hospital burden of CDI have been extracted, compared, and discussed from four public databases for the years 2010-2019. Hospital days due to CDI were compared to established vaccine preventable diseases, such as influenza and herpes zoster, and also to CDI hospitalisations in the United States (US).

resultsAll four databases reported comparable incidences and trends. Beginning in 2010, population-based hospitalised CDI incidence increased to a peak of > 137/100,000 in 2013. Then, incidence declined to 81/100,000 in 2019. Hospitalised patients with CDI were predominantly > 50 years of age. The population-based incidence of severe CDI was between 1.4 and 8.4/100,000 per year. Recurrence rates were between 5.9 to 6.5%. More than 1,000 CDI deaths occurred each year, with a peak of 2,666 deaths in 2015. Cumulative CDI patient days (PD) were between 204,596 and 355,466 each year, which exceeded cumulated PD for influenza and herpes zoster in most years, though year-to-year differences were observed. Finally, hospitalized CDI incidence was higher in Germany than in the US, where the disease is well recognized as a public health threat.

conclusionsAll four public sources documented a decline in CDI cases since 2013, but the disease burden remains substantial and warrants continued attention as a severe public health challenge.

Indexed as

Burden of diseaseClostridioides difficileGermanyHospitalIncidenceSurveillance

Identifiers

PMID36897556
PMCPMC10000342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.